Posts
- International Women's Day 2023 - 8 March 2023
- Contact Us - Products
- Our Product Portfolio
- Your Expert: YEX010 - Preview
- Privacy Policy
- NIPT
- 25 January 2023 - Directorate Change
- MyNIPT
- Atlas Workflow Manager
- DPYD - Events Live
- NIPT - Events Live
- Our Services
- Reproductive Health - Events Live
- Events Live Form
- All Events
- IONA® Analysis Software
- Yourgene Flex™ Analysis Software
- Yourgene® QS250
- Ranger® Technology - Events Live
- Yourgene Genomic Services Customer Login
- Contact Us
- Privacy
- Extraction Services
- Microarrays
- Polymerase Chain Reaction (PCR)
- Dr John Brown: <br>Non-executive Chairman
- Mary Tavener: <br>Non-executive Director
- Andy Leeser: <br>Non-executive Director
- Jonathan Seaton: <br>Non-executive Director
- Lyn Rees: <br>Chief Executive Officer (Director)
- Dr Bill Chang, Ph.D: <br>Chief Entrepreneur
- Dr Joanne Mason: <br>Chief Scientific Officer
- Corporate Governance
- Investor Films
- Investor Presentations
- Shareholder Communications
- Financial Reports
- RNS
- Key Documents
- Shareholder Information
- AIM Rule 26
- Company Information
- Dr Robert Henke: <br>Vice President of Sales - Asia Pacific
- Darren Marjenberg: <br>Vice President of Sales - EMEA
- NIPT
- Join our Team
- Our Locations
- Scott Sargent: <br>Vice President of Sales - Americas
- Joanne Cross: <br>Director of Marketing
- Matthew Nesbitt: <br> Product Specialist Director
- Your Comment
- Events
- Product Menu (CE-IVD & RUO)
- Wendy Cox: <br>HR Director
- Peter Coyne: <br>Vice President of Global Operations
- Order a Test
- Enquirer Information Form - YEX012
- Your Expert
- Yourgene Health Customer and Distributor Portal
- Yourgene Health Customer Login
- +RNAinsight® powered by Ambry® Genetics
- CancerNext® powered by Ambry Genetics
- Chemotherapy Resistance (DPYD)
- NIPT Extended menu
- Trisomies by NIPT
- Press Releases
- 25 Aug 2022 - Notice of AGM, Change of Registered Address and Investor Presentation
- 16 August 2022 - Open Day and advance notice of AGM
- Clinical Research
- Our Business
- Our People
- Quality and Regulatory
- Our News
- Our Partners
- About Us
- Next Generation Sequencing (NGS)
- Pharma Services
- PCR
- NGS
- Cancer Precision Medicine Panel
- DPYD Genotyping
- Thrombosis Risk Panel
- Male Factor Infertility
- Pregnancy Loss
- Rapid Aneuploidy Analysis
- Cystic Fibrosis
- the IONA® test
- NIPT
- Next Generation Size Selection
- Yourgene® SP150
- LightBench®
- NIMBUS Select
- LightBench® Detect
- 27 July 2022 - Dr John Brown CBE confirmed as Chairman
- 27 July 2022 - Audited Final Results
- Ranger® Revolution - LightBench® Detect is here! - 20 June 2022
- 24 May 2022 - Launch of the Accelerator Phase for Microdeletions Plugin
- Collaboration to Perform: Yourgene Microdeletions Plugin Accelerator - 24 May 2022
- 26 April 2022 - Directorate Change
- 26 April 2022 - Full year trading update
- 25 April 2022 - Strategic partnership extended with Ambry Genetics
- 06 April 2022 - Capital Markets Day
- 17 February 2022 - Successful CTDA desktop review
- Exclusion criteria for NIPT explained - 15 February 2022
- International Women and Girls in Science Day 2022
- 25 January 2022 - Directorate Change
- 19 January 2022 - Agreement of new debt facility
- 19 January 2022 - Opening of new Yourgene Health Canada Inc. facilities
- New Year, New Regulations - 19 January 2022
- 18 January 2022 - US partnership with EKF Diagnostics for NIPT and additional genomic tests
- 17 January 2022 - Current year trading update
- 23 Dec 21 - DHSC contract awarded to support COVID-19 Winter surge testing
- 14 December 2021 - UKHSA contract award
- 14 December 2021 - Half-year Report
- 18 November 2021 - DPYD screening recommended in Spain
- Behind the scenes: Adapting diagnostic services during a pandemic - 11 November 2021
- Overprescribing within the NHS - 02 November 2021
- 28 October 2021 - Yourgene’s Ranger Technology to be presented at Labroots webinar
- 26 October 2021 - Half-year Trading update
- 19 April 2021 - Further National Microbiology Framework contract award
- 28 September 2021 - AGM Statement Investor presentation
- 10 September 2021 - Further re: DHSC contract secured to support COVID-19 surge testing
- 1 September 2021 - Yourgene Genomic Services receive ISO 15189:2012 accreditation
- 1 September 2021 - Notice of AGM and Annual Report 2021
- 19 August 2021 - Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing
- The role genomics plays in relationships - 18 August 2021
- 11 August 2021 - Earn-out Milestone, Issue of Equity & Total Voting Rights
- 11 August 2021 - Audited Final results and unaudited Q1 business update
- 21 June 2021 - Second Strategic Partner for Coastal Genomics
- 18 June 2021 - Contract Award for the supply of DPYD testing kits to NHS Wales
- 9 June 2021 - Multi-year licence and supply agreement with leading US precision medicine company
- NIPT for Sex Chromosome Aneuploidies and Autosomal Aneuploidies. A Q&A with Dr Greg Fitzgibbon - 26 May 2021
- 19 May 2021 - Distribution Partnership for the Middle East and Africa
- 18 May 2021 - Launch of IONA® Care NIPT service offering
- 17 May 2021 - Further testing service agreement for MyHealthChecked plc
- COVID-19 testing and the need for regulation - 6 May 2021
- 29 April 2021 - Full year Trading update
- 26 April 2021 - Further National Microbiology Framework contract awards
- Yourgene on World Creativity and Innovation Day 2021 - 21 April 2021
- 19 April 2021 - National Framework contract award for Covid-19 testing products and services
- The IONA® test recommended for twin pregnancies screening for Down’s syndrome - 7 April 2021
- 6 April 2021 - Testing service agreement with MyHealthChecked plc
- 29 March 2021 - COVID-19 update
- Blood clots, inherited thrombophilia and COVID-19 - 25 March 2021
- 19 March 2021 - Twin Pregnancy study published using Yourgene’s IONA® Test
- 17 March 2021 - Appointment of VP of Sales North America
- 11 March 2021 - Yourgene Genomic Services portfolio expansion
- 1 March 2021 - First US Supply Agreement for Coastal Genomics' Technology Signed with Major Strategic Partner
- 22 February 2021 - Partnership with NPH
- 8 February 2021 - Trading update
- COVID-19 strains - what are they and why do they matter? A Q&A with Dr Michael Risley - 28 January 2021
- 13 January 2021 - DPYD screening recommended in Belgium
- 11 January 2021 - Clarigene® SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19
- 24 December 2020 - COVID-19 update: approved provider for UK Government and response to new virus strain
- So much to be proud of! - 23 December 2020
- 17 December 2020 - Half-year Report
- 2 December 2020 - DPYD kits recommended by NHS England
- COVID-19 vaccines and the continued role of testing - 16 November 2020
- 5 November 2020 - Directorate change
- The role of DPYD testing in managing a successful response to the COVID-19 pandemic - 5 November 2020
- 3 November 2020 - Partnership with Take2 Health Limited
- 26 October 2020 - Half-year Trading update
- 23 October 2020 - CQC registration
- 21 October 2020 - Yourgene Genomic Services collaboration with Cytox
- 14 February 2020 - Medilink Award win for Outstanding Achievement
- 12 October 2020 - Elucigene DPYD tests to be used routinely in Wales
- 8 October 2020 - Strategic reproductive health partnership secured in Japan
- 7 October 2020 - IONA® Nx awarded contract with St George’s NHS Hospital
- 3 August 2020 - CE-IVD Mark for Clarigene™ SARS-CoV-2 test
- 28 September 2020 - Launch of Yourgene Genomic Services
- 24 September 2020 - DPD reimbursement in Germany
- 22 September 2020 - AGM statement
- 21 September 2020 - US distribution agreement for DPYD and other products
- 3 September 2020 - IONA® Nx Launch
- 13 August 2020 - TGA approves IONA® Nx for sale in Australia
- 5 August 2020 - Result of Placing
- 5 August 2020 - Successful £16.15 million Placing & Close of Accelerated Bookbuild
- 4 August 2020 - Proposed Acquisition and Placing to raise a minimum of £13 million
- 28 July 2020 - Final Results
- 30 June 2020 - COVID-19 assay launched
- 16 June 2020 - Collaboration in COVID-19 testing
- 15 June 2020 - CE-IVD mark received for Illumina-based IONA® test
- 26 May 2020 - Yourgene COVID-19 testing service launch and business update
- 20 April 2020 - Year-end Trading update: Revenues increase 86%
- 7 April 2020 - Presentation on ‘Adapting during crisis’
- 25 March 2020 - Contract manufacturing agreement for COVID-19 diagnostic test
- 10 March 2020 - Acquisition of French distribution channel & Direct Subscription to raise £2.5m
- 17 February 2020 - CE Marking Technical File submission
- 14 February 2020 - TGA approves DPYD for sale in Australia
- 2 December 2019 - Half-year Report
- 29 November 2019 - Bionow Double Award Wins
- 28 November 2019 - Opening of New Facilities and Corporate HQ
- 31 October 2019 - Launch of Yourgene Flex™ Analysis Software
- 15 October 2019 - American Society of Human Genetics Annual Meeting attendance
- 14 October 2019 - Half year trading update
- 26 September 2019 - CE-IVD Certification renewal
- 18 September 2019 - Launch of DPYD chemotoxicity diagnostic assay
- 20 August 2019 - Notice of AGM
- 16 August 2019 - Directorate Change Appointment of business development sector specialist as Non-executive Director
- 29 July 2019 - Appointment of Director
- 10 July 2019 - Results for the Year Ended 31 March 2019, Business Update and Director Change
- 9 July 2019 - Results for the Year Ended 31 March 2019 Business Update, Director Change
- 24 June 2019 - Yourgene participates in key global conferences
- 25 April 2019 - Completion of Acquisition
- 17 April 2019 - Proposed acquisition of Delta Diagnostics (UK) Limited
- 8 April 2019 - Full-year Trading Update
- 25 March 2019 - Yourgene raises IONA® test awareness in Egypt with British Ambassador (2)
- 18 February 2019 - Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder
- 8 January 2019 - High throughput NIPT solution for clinical laboratories
- 3 December 2018 - Half-year Results
- 7 November 2018 - Change of Name to Yourgene Health plc & Change of Website Address
- 12 October 2018 - Trading Update & Notice of Results
- 04 October 2018 - $1 million collaboration agreement
- 28 September 2018 - Proposed fundraise to raise approximately £2.5 million
- 28 September 2018 - Full year results to 31 March 2018 and half-year trading update
- 20 September 2018 - Senior Commercial Appointment and Anticipated Directorate Change
- 19 September 2018 - Legal Settlement and Licence Agreement with Illumina
- 4 July 2018 - Board Changes
- 26 June 2018 - Collaboration with Abnova
- 13 June 2018 - Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award
- 11 June 2018 - Partnership agreement for DNA sequencing technology development
- 5 June 2018 - Premaitha signs NIPT partnership agreement in India
- 15 May 2018 - Premaitha expands footprint with new laboratories in Kenya and India
- 15 May 2018 - Year-end Trading Update and £2.5m Fundraising
- 29 March 2018 - Premaitha to attend key industry conferences in Asia Pacific
- 26 March 2018 - Update on UK patent infringement claim received in September 2017
- 16 February 2018 - Premaitha secures market entry into Egypt
- 6 February 2018 - Premaitha raises awareness of the IONA® test at key conferences in the Middle East
- 5 February 2018 - Premaitha’s IONA® test approved for sale in Brazil
- 29 December 2017 - Half Year Results
- 11 December 2017 - Premaitha secures four further laboratories in Europe
- 01 December 2017 - Premaitha CEO Wins Bionow Outstanding Contribution Award
- 27 November 2017 - Middle East laboratory network expansion
- 23 November 2017 - Premaitha signs new partner to offer NIPT solution in East Asia
- 21 November 2017 - Litigation First Instance Judgment
- 13 October 2017 - Commercial progress in the Middle East
- 29 September 2017 - Full year results to 31 March 2017 and half-year trading update
- 19 September 2017 - Premaitha to offer NIPT in South Africa
- 7 September 2017 - Further patent infringement claims received from Illumina & Sequenom
- 29 August 2017 - Premaitha approved for Good Manufacturing Practice by ANVISA Brazil
- 12 July 2017 - Investment Agreement Extension with Thermo Fisher Scientific
- 10 July 2017 - Premaitha announces two laboratory hub contracts in South East Asia
- 3 July 2017 - Litigation Update
- 26 June 2017 - The IONA® test updated to include the first trimester combined test result
- 16 June 2017 - Premaitha launches Sage™ prenatal screening solution in Hong Kong
- 5 June 2017 - India Business Update
- 26 May 2017 - Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument
- 19 May 2017 - Premaitha welcomes NIPT recommendation in France
- 12 May 2017 - Update Re. Swiss Customer
- 13 March 2017 - Premaitha Raises Awareness of the IONA® Test at Key International Medical Events
- 27 February 2017 - Completion of Yourgene Acquisition, Issue of Shares and Director Appointments
- 20 February 2017 - Middle East Business Update
- 16 February 2017 - Publication of scientific paper on Premaitha’s IONA® test
- 15 February 2017 - Issue of Equity
- 13 February 2017 - New partnership with major European diagnostics group
- 7 February 2017 - Southern Europe Business Update
- 21 December 2016 - Half Year Results
- 21 December 2016 - Conditional Acquisition of Yourgene Bioscience and Posting of Circular
- 21 November 2016 - Premaitha establishes first service laboratory customer in Asia
- 31 October 2016 - NHS to adopt NIPT for high risk women
- 27 October 2016 - AGM Statement
- 30 September 2016 - Annual Results 2016
- 23 September 2016 - Investment agreement extension with Thermo Fisher Scientific
- 4 July 2016 - Progress on anti-trust objections to litigation
- 27 June 2016 - Launch of MyNIPT™ Online Portal for the IONA® test
- 22 April 2016 - Update on competitor patent litigation
- 20 April 2016 - Patent litigation rescheduled
- 29 March 2016 - Premaitha announces tenth customer laboratory
- 21 March 2016 - Premaitha Enters Middle East with Series of Regional Laboratory Hubs
- 11 March 2016 - Premaitha wins at North West Business Masters Awards 2016
- 9 March 2016 - Premaitha signs distribution agreement with GeNext in Russia
- 3 February 2016 - Premaitha Health partners with Visional Medical to provide the IONA® test to pregnant women in India
- 2 February 2016 - Premaitha Health partners with Leeds Teaching Hospitals NHS Trust to offer pregnant women safer non-invasive prenatal screening service
- 27 January 2016 - Premaitha Health signs two new customers for its clinical laboratory NIPT screening service
- 26 January 2016 - Update on UK Litigation Timing
- 15 January 2016 - Premaitha Health welcomes recommendation for NHS provision of non-invasive prenatal testing
- 8 January 2016 - Update on competitor patent litigation
- 5 January 2016 - Premaitha Health launches Workflow Manager system for the IONA® test to support clinical laboratory customers
- 14 December 2015 - Results for the half year ended 30 September 2015
- 14 December 2015 - Premaitha Health signs Investment Agreement with Thermo Fisher Scientific
- 2 December 2015 - Premaitha establishes the first IONA® testing service in France at LaboSud
- 12 November 2015 - Independent, multi-centre clinical study of the IONA® test in high risk pregnancies shows 100% detection of trisomies and 0% false positives
- 14 October 2015 - Premaitha opens dedicated clinical laboratory with expanded capacity to meet demand for IONA® test service
- 13 October 2015 - In-house Antenatal reflex DNA screening for Down’s syndrome, trisomy 18 and trisomy 13: a world first
- 12 October 2015 - Independent performance study of the IONA® test published
- 2 October 2015 - Premaitha appoints Antisel SA to distribute the IONA® test in Greece
- 1 October 2015 - Illumina Patent Infringement Proceedings Update
- 22 September 2015 - Premaitha signs first non-European partnership with Servicios Genéticos OriGen to provide the IONA® test for pregnant women in Chile
- 2 July 2015 - Completion of placing to raise £8 million
- 2 July 2015 - Proposed placing to raise approximately £8 million
- 24 June 2015 - New IONA® test clinical data showcased
- 22 June 2015 - New contract for IONA® test
- 15 June 2015 - Clinical and performance data from the IONA® test to be presented at the World Congress in Fetal Medicine, Crete
- 6 July 2015 - Premaitha Health receives CQC accreditation for new NIPT clinical service laboratory to support IONA® test customers
- 4 June 2015 - Directorate Change
- 22 May 2015 - Premaitha Health wins Medical & Lifescience Award
- 5 May 2015 - Premaitha files robust defence with UK’s High Court in response to alleged infringement of NIPT patents
- 31 March 2015 - Centrum Badan DNA partners with Premaitha Health to offer the IONA® test in Poland
- 23 March 2015 - Leading London NHS trust teams up with Premaitha Health to create the UK’s first Centre of Excellence for non-invasive prenatal screening
- 16 March 2015 - Premaitha Health and Esperite NV sign a collaboration agreement for NIPT provision in Europe
- 16 March 2015 - Notice of Patent Infringement Proceedings
- 5 February 2015 - Premaitha Health Launches the IONA® test, the First Ever CE-marked NIPT Product for Pregnant Women
- 30 January 2015 - Premaitha Health Receives ISO 13485:2003 Certification and Meets Annex IV of the In Vitro Diagnostic Medical Device Directive
- 28 November 2014 - Premaitha Health Wins Bionow Investment Deal of the Year Award
- 6 November 2014 - Premaitha Health Prepares for Launch of the IONA® test with Key Commercial Appointment
- 4 July 2014 - Premaitha Looks to Deliver Diagnostic Test Product to Improve Prenatal Screening Globally
- 13 June 2014 - Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally
